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Background In mature generalized human immunodeficiency virus (HIV) epi-
demics, as survival from accessing antiretroviral treatment (ART)
increases, HIV prevalence data may be suboptimal and difficult to
interpret without HIV incidence rates.
Objective To determine the HIV incidence rate among rural and urban
women in KwaZulu-Natal, South Africa.
Methods We conducted a prospective cohort study from March 2004 to May 2007.
Volunteers were recruited from a rural family-planning clinic and
an urban clinic for sexually transmitted infections. Consenting, HIV-
uninfected women aged 14–30 years were enrolled. Demographic, clin-
ical, sexual and behavioural data were collected using standardized
questionnaires with HIV risk reduction counselling and HIV testing.
Pelvic examinations were completed at quarterly visits.
Results The HIV prevalence at screening was 35.7% [95% confidence interval
(CI) 32.7–38.8] amongst rural women and 59.3% (95% CI 56.5–62.0)
amongst urban women. A total of 594/2240 (26.5%) enrolled women
contributed to 602 person-years (PYs) of follow-up. The median age
was 22 years [inter-quartile range 18–23 years]. HIV incidence rate
was 6.5/100 PY (95% CI 4.4–9.2) amongst rural women and 6.4/100 PY
(95% CI 2.6–13.2) amongst urban women. HIV incidence rate of
17.2/100 PY (95% CI 2.1–62.2) was highest amongst urban women
<20 years of age and 10.2/100 PY (95% CI 4.1–20.9) amongst rural
women 525 years of age.
Conclusion HIV incidence rates are devastatingly high in young women in rural
and urban KwaZulu-Natal, despite reports of stabilized HIV preva-
lence observed in current surveillance data. The diffuse nature of
the HIV epidemic underscores the urgent need to enhance HIV
prevention and treatment modalities.
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South Africa has the highest burden of human im-
munodeficiency virus (HIV) infection in the world
with an estimated 5.7 million people infected with
HIV in 2008.1 The province of KwaZulu-Natal is at
the epicentre of the pandemic, and women account
for 460% of infections.2–4 The epidemic typology has
been described as ‘hyperendemic, generalized and
mature’5 to reflect415.0% HIV prevalence in the general
population.2 Annual, anonymous, antenatal surveys
undertaken since 1990 have served as the mainstay
of HIV surveillance for monitoring trends in the evol-
ving epidemic, for priority setting and health-service
planning. Data from these surveys in the past 3 years
demonstrate a stabilization of national HIV prevalence
estimates.6
With increasing access to antiretroviral treatment
(ART),7 HIV prevalence is expected to increase result-
ing from increased survival.8 Notwithstanding the
challenges to increasing ART access and coverage,7,9
knowledge of the epidemic is key to customizing
responses.5,10,11 In the early stages of the epidemic
where disease burden and mortality rates are low,
HIV prevalence data provide a reliable marker for
monitoring the epidemic.12 However, as the epidemic
matures morbidity and mortality increases;3,13,14 inci-
dence rate data8,15–17 are important to understand on-
going transmission dynamics and inform the
prioritization of prevention efforts, whereas preva-
lence of established infections informs health service
and care planning needs.5,10
As laboratory methods to differentiate established
and new infections are being validated, cohort studies
provide an option for ascertaining rates of new HIV
infections. This prospective cohort study was
undertaken in a rural and urban setting to better
understand the stabilized HIV prevalence data in
KwaZulu-Natal and to assess the feasibility of under-
taking HIV prevention studies with incident HIV in-
fections as endpoints.
Methods
Study design, setting and source population
The Centre for the AIDS Programme of Research in
South Africa (CAPRISA) is an AIDS research institute
in KwaZulu-Natal, South Africa conducting research
that contributes to understanding HIV epidemiology,
prevention and pathogenesis, as well as the links
between tuberculosis and AIDS care. This prospective
cohort study was undertaken at CAPRISA’s two
clinical research sites.
The CAPRISA Vulindlela Clinical Research site (rural
site) is located 150 km north-west of Durban. This
community has approximately 400 000 residents, with
limited resources, infrastructure and employment
opportunities accounting for high levels of poverty
and unemployment.18 Health services are provided
by seven public-sector primary health-care clinics
and the closest referral hospitals are 30 km away.
From March 2004 to April 2005, volunteers were
recruited from the rural family planning clinic. The
CAPRISA eThekwini Clinical Research site (urban
site) is located in central Durban adjacent to a large
public-sector primary-care clinic designated for the
diagnosis and treatment of sexually transmitted infec-
tions (STIs) and tuberculosis. From July 2005 to
December 2005, female volunteers were recruited
from the STI clinic. Based on cross-sectional survey
data, HIV incidence rates are highest in young
women and establishing cohorts of young
women aged 14–30 years, although this age cut-off
reduces generalizability, targets women at highest
HIV risk.
Study procedures
Volunteers aged 14–30 years received study informa-
tion, provided written informed consent and were
screened for eligibility to assess willingness to provide
adequate locator data for study retention purposes, be
sexually active (defined as having had vaginal inter-
course at least once in the 3 months prior to screen-
ing) and test HIV negative. Women were excluded
if planning to travel away from the study site for
43 consecutive months in the 12 months following
enrolment; plans to migrate outside the study catch-
ment area in the 12 months following enrolment;
plans to become pregnant in the next 2.5 years
post-enrolment; or enrolled in any other study of a
vaginally applied product related to HIV prevention.
At enrolment and at each monthly visit, demograph-
ic, clinical, sexual and behavioural data were obtained
from all women through nurse-administered inter-
views using structured questionnaires. Women were
tested for HIV and pregnancy, received HIV and risk
reduction counselling and were offered male and
female condoms. At enrolment, quarterly and at
study exit visits, pelvic examinations were completed
and blood samples collected for archiving for retro-
spective confirmation of HIV endpoint. Women were
reimbursed minimally at each visit for time and travel
costs as per the South African National Ethics
Guidelines.19
Laboratory testing procedures
HIV testing was performed on-site using two rapid anti-
body tests (Determine HIV-1/2—Abbott Laboratories,
IL, USA and HIV-1/2 SmartCheck assay—
Globalemed.LLC, World Diagnostics, Inc.). Women
testing concordantly positive, indeterminate or dis-
cordant at follow-up visits had blood sample collected
at the same visit for HIV antibody testing (Enzygnost
Anti-HIV-1/2 Plus, Dade Behring, Marburg, Germany)
and HIV-1 RNA polymerase chain reaction (PCR)
assay [COBAS AmpliScreen HIV-1 Test, version
1.5 (Qualitative) and AMPLICOR HIV-1 MONITOR
Test, v1.5 (Quantitative); Roche Molecular Systems,













Inc., Branchburg, NJ, USA]. Incident HIV infection was
confirmed on positive HIV-1 RNA PCR (qualitative and
quantitative) and/or HIV antibody positive, and
negative on the last stored blood sample tested retro-
spectively. Urine pregnancy testing was performed on
site (QuickVue One-Step hCG Urine Test; Quidel
Corporation, San Diego, USA).
Ethical considerations
The protocol, informed consent and data collection
forms were reviewed and approved by the University
of KwaZulu-Natal Biomedical Research Ethics com-
mittee. The screening and enrolment visits were
undertaken on different days to give eligible women
sufficient time to consider their decision to participate
in this study.
At both sites, community engagement processes were
established through Community Research Support
Groups (CRSG) consisting of stakeholders including
health-service providers and traditional leaders from
community structures. The community liaison officers
worked closely with CRSG members on a regular basis
to disseminate information on the epidemiology of
HIV epidemic in South Africa, HIV prevention strategies
and the rationale for conducting HIV prevention
research and HIV treatment.
At screening, women identified with HIV infection
were referred to the CAPRISA AIDS Treatment
Program operational at both sites. Pregnant women
identified during screening or follow-up were referred
to local public-sector facilities for follow-up antenatal
care but continued with their monthly study visits.
Women diagnosed with symptomatic STIs were man-
aged syndromically on site as per the South African
Department of Health guidelines.20 Contraceptive
counselling and contraceptives were provided at
both sites as part of the study visit. Women who
became HIV infected were given the option of joining
the CAPRISA Acute HIV-1 Infection Study or the
CAPRISA AIDS Treatment Project for ongoing care
and support.
Data collection and statistical analysis
Data were collected on standardized case report forms
(CRFs) and faxed to a dedicated study database using
DataFax (Clinical DataFax Systems Inc., Hamilton,
Canada). For quality assurance, all CRF entries were
manually and electronically verified and the quality of
the data reviewed in real time. Data analysis was
undertaken with Statistical Analysis Software (SAS)
statistical package (version 9.1.3; SAS, NC, USA).
The baseline variables were summarized using
descriptive statistics expressed as mean or median
for continuous variables and as percentages for cat-
egorical variables. For statistical testing for differ-
ences, the Fisher’s exact test comparing categorical
data and Wilcoxon rank sum test for continuous
data were used. McNemar’s agreement statistic was
used for analysis of paired categorical data with two
categories, Bowker’s test of symmetry for paired
categorical data with more than two levels and
Wilcoxon signed rank sum test for paired continuous
data. Missing data were not included in the com-
parison between baseline and 12 months. All analyses
were two-sided.
HIV incidence rate was estimated on the number of
confirmed seroconversions, calculated per 100 person-
years (PYs) at risk. The time at risk was defined as
the time from enrolment to the last negative HIV test
for women who remained HIV uninfected or the first
confirmed positive HIV test result for those who became
infected during the study. Pregnancy rate was estimated
on the number of positive urine pregnancy tests,
calculated per 100 PYs. Time at risk excluded the
time from a positive pregnancy test to pregnancy
outcome. Confidence intervals (CIs) for HIV and preg-
nancy incidence rate assumed a Poisson distribution.
Results
Screening, accrual and retention
A total of 2240 (981 rural and 1259 urban) volunteers
were screened. HIV prevalence was 35.7% (95% CI
32.7–38.8) amongst rural women and 59.3% (95% CI
56.5–62.0) amongst urban women; the main reason
for exclusion of volunteers. At both sites, HIV preva-
lence was highest amongst volunteers 25 years and
older compared with younger volunteers (both sites
P < 0.001) (Table 1). Other reasons for ineligibility
included volunteers being overage (13.8%), not
returning for enrolment visit (5.8%), not sexually
active (3.0%), requesting voluntary counselling and
testing services only (1.2%), pregnancy (0.2%), plan-
ning to relocate from current address (0.1%), fear
of study procedures especially pelvic examinations
(0.2%), medical reasons (0.2%) and partner not
agreeing to her participation in research (0.01%).
A total of 594 (26.6%) women were enrolled with
a mean enrolment rate per month per site of
26 (rural) and 17 (urban) women with a screening
to enrolment ratio of 1:2 and 1:10, respectively. The
overall retention rate was 70.0% (95% CI 65.7–73.9)
and 78.0% (95% CI 70.2–85.3) at the rural and urban
sites, respectively. There were no differences in
women who completed the study compared with
those who did not return for follow-up with regard
to demographic characteristics of age, completion of
secondary schooling, relationship status, living with
partner or whether they were from the rural or
urban site (all P40.05). At exit, there were 477 and
117 women at the rural and urban site, respectively,
with a cumulative of 602 PYs.
Demographic characteristics
All enrolled women were Black African with an over-
all median age of 22 years [inter-quartile range (IQR)
18–23 years]. Rural women compared with urban













women were younger; a higher proportion were
<20 years of age and had not completed secondary
schooling (all P < 0.001). Majority of women reported
to be in a stable relationship though they were currently
not living with their sexual partner (Table 2).
Sexual behaviour characteristics
Sexual behaviour data at baseline and at 12 months
follow-up are presented in Table 3. Amongst rural
women, there was a reduction in the mean number
of sex acts reported in the 2 weeks preceding
their Month 12 study visit (P¼ 0.03), increase in
reported condom use with vaginal sex (P < 0.001),
decline in the proportion reporting one sex partner
in the past 3 months (P¼ 0.004) with no changes
in contraceptive-use patterns (P¼ 0.05), although a
higher proportion of women reported engaging in
anal sex (0.8 vs 1.5%; P¼ 0.18). In contrast, among
urban women there was a decline in anal-sex practice
(6.8 vs 1.3%, P¼ 0.03), no decline in the mean
number of sex acts in the past 2 weeks preceding
their Month 12 study visit (P¼ 0.17), or the percent-
age of women reporting one partner in the past
3 months (P¼ 0.37), or changes in contraceptive-use
patterns (P¼ 0.48) and condom use during last
vaginal sex act (P¼ 0.10).
The practice of intra-vaginal substance use of water
with salt, vinegar, soap or douching with antiseptics
containing parachlorometaxylenol or povidone iodine
products or traditional herbs was used for personal
hygiene. Despite counselling on potential HIV risk,
we did not observe any changes in these practices in
rural women (17.6 vs 12.0%, P¼ 0.07). The self-report
of STIs (genital ulceration and/or vaginal discharge)
declined at 12 months amongst rural (25.4 vs 4.5%,
P < 0.0001) and urban women (28.2 vs 5.2%,
P < 0.0001); however, any abnormal pelvic examin-
ation finding (vaginal discharge, vaginitis, cervicitis,
ulceration, abrasions, petechia, vesicles or genital
warts) declined amongst rural women only (39.6 vs
15.4%, P < 0.0001) and not amongst urban women
(36.8 vs 30.9%, P¼ 0.35).
Incidence of HIV
As shown in Table 4, a total of 39 (6.6%) women
became HIV infected during the study. The HIV inci-
dence rate was 6.5/100 PY (95% CI 4.4–9.2) amongst
rural women and 6.4/100 PY (95% CI 2.6–13.2) amongst
urban women. The highest rate of 17.2/100 PY (95% CI
2.1–62.2) was among urban women <20 years of age,
whereas the rate of 10.2/100 PY (95% CI 4.1–20.9) was
highest amongst older rural women, 525 years of age.
HIV incidence rate was higher amongst older rural
women compared with younger women [10.2/100 PY
(95% CI 4.1–20.9) vs 3.6/100 PY (95% CI 1.7–6.9),
(P¼ 0.03)].
Table 1 HIV prevalence and screening outcome of rural (March 2004 to April 2005) and urban (July to December 2005)
women aged 14–30 years in KwaZulu-Natal, South Africa
Overall Rural Urban
HIV prevalence
Number screened 2240 981 1259
n/N % (95% CI) n/N % (95% CI) n/N % (95% CI)
HIV prevalence 1096/2240 48.9 (46.8–51.0) 350/981 35.7 (32.7–38.8) 746/1259 59.3 (56.5–62.0)
Age-specific HIV prevalencea
<20 years 101/378 26.7 (22.4–31.5) 47/245 19.2 (14.6–24.8) 54/133 40.6 (32.3–49.5)
20–24 years 283/694 40.8 (37.1–44.6) 81/258 31.4 (25.9–37.5) 202/436 46.3 (41.6–51.1)
525 years 575/870 66.1 (62.8–69.2) 85/180 47.2 (39.8–54.8) 490/690 71.0 (67.5–74.4)
Screening outcome n % n % n %
HIV positive 1096 48.9 350 35.7 746 59.3
Age 430 years 308 13.8 21 2.1 287 22.8
Pregnant 5 0.2 0 0.0 5 0.4
Not sexually active 68 3.0 65 6.6 3 0.2
Voluntary counselling and testing 27 1.2 0 0.0 27 2.1
Planning to move away 3 0.1 0 0.0 3 0.2
Afraid of clinical procedures 4 0.2 4 0.4 0 0.0
Medical reasons 4 0.2 0 0.0 4 0.3
Partner refusing 1 0.0 0 0.0 1 0.1
Not returning for enrolment 130 5.8 64 6.5 66 5.2
aMissing age for 298 women.














A total of 96 women (16.2%) became pregnant during
the study (Table 4), out of which 74 were rural
and 22 urban. The pregnancy incidence rate was
16.6/100 PY (95% CI 13.1–20.9) among rural women
and 22.4/100 PY (95% CI 14.1–34.0) among urban
women. The highest pregnancy incidence rate of
30.6/100 PY (95% CI 6.3–89.3) was amongst young
urban women <20 years of age.
Of the women who became pregnant, 50 (52.1%)
reported not having used any form of contraception,
32 (33.3%) reported relying on partners using male
condoms only, 9 (17.3%) and 5 (5.2%) reported to
be on injectable or oral forms of contraception,
respectively. Not surprisingly, women on hormonal
contraception who became pregnant reported being
non-adherent to contraceptive use.
Of the 96 pregnancies, 62 (64.6%) continued to
full term, 20 (20.8%) were still pregnant at exit,
5 (5.2%) resulted in spontaneous abortion or
had elective termination of pregnancy and in 9
(9.4%) the outcome was unknown. Should women
in a trial of an investigational new drug become
pregnant, for safety reasons they would be
required to go off product for the duration of the
pregnancy and the pregnancy time would translate
to 58.7 PY.
Discussion
In this sample of rural and urban women in
KwaZulu-Natal, HIV incidence rates of 6.5/100 PY
and 6.4/100 PY, respectively, are devastatingly
Table 3 Changes in sexual behaviour from enrolment and at 12 months among rural and urban women aged 14–30 years











Mean number of vaginal sex acts in the
past 2 weeks (range)
2 (0–11) 1.8 (0–18) 0.03 2 (0–20) 2 (0–8) 0.17
Mean percentage condom use with vaginal
sex in the past 2 weeks (range)
30.5 (0–100) 58.0 (0–100) <0.0001 41.9 (0–100) 61.3 (0–100) 0.10
Percentage with one sex partner in the
past 3 months
98.5 94.3 0.004 82.1 92.3 0.37
Percentage reporting anal sex 0.8 1.5 0.18 6.8 1.3 0.03
Percentage not using contraception 21.8 10.9 0.05 29.1 34.6 0.48
Percentage using injectable hormonal
contraception
55.1 63.9 18.8 32.1
Percentage using oral hormonal
contraception
5.9 6.8 4.3 3.7
Percentage with any form of vaginal
insertions
17.6 12.0 0.07 41.9 9.9 <0.0001
Percentage with sexually transmitted
infectionsa
25.4 4.5 <0.0001 28.2 5.2 0.0002
Percentage with any abnormalb
pelvic examination
39.6 15.4 <0.0001 36.8 30.9 0.35
aGenital ulceration and or vaginal discharge.
bAny abnormality of vaginal discharge, vaginitis, cervicitis, ulceration, abrasions, petechia, vesicles and/or warts.
Table 2 Socio-demographic characteristics of rural and
urban women at enrolment comprising the study population
in KwaZulu-Natal, South Africa
Characteristic
Overall Rural Urban
N¼ 594 N¼ 477 N¼ 117
% % %
Age group in years
<20 41.1 47.6z 14.5z
20–24 40.6 34.8z 64.1z
525 18.4 17.6 21.4



















aMarried (2.7% rural and 3.4% urban).
zP < 0.001; yP¼ 0.001.













high, yet similar to the 7.2/100 PY reported for
self-identified female sex workers in Durban,21
6.0/100 PY among women in rural Hlabisa, northern
KwaZulu-Natal, and 5.0/100 PY amongst urban
women in Durban.22 Regardless of the stabilizing
HIV prevalence observed in the antenatal6 and
population-based surveys,2 these high HIV incidence
rates are disturbing. In contrast, HIV incidence rates
from many southern African countries are compara-
tively lower, ranging from 1.3/100 PY in Moshi,
Tanzania, to 2.6/100 PY in Lusaka, Zambia,22,23 to
4.2/100 PY in Lilongwe, Malawi, 4.5/100 PY in
Blantyre, Malawi, to 4.8/100 PY in Harare,
Zimbabwe.24,25 Of note in all of these studies is that
these high incidence rates are being reported in the
context of substantial amounts of counselling and
promotion of abstinence, behaviour change, condom
use and know-your-HIV-status paradigm. In the ab-
sence of this intensity of counselling and prevention
support, the reported incidence rates are likely to be
even higher.
At screening, a large number of women older than
age 25 years were already infected with HIV and were
unaware of their HIV status. For many women this
was their first opportunity to have an HIV test. This
highlights the importance for increasing provider-
initiated HIV counselling and testing services.26 The
high HIV prevalence in both rural and urban
women provides an indication of the enormous
AIDS care and treatment needs and anticipated
disease burden on health-care services.
HIV prevalence has been used to measure burden of
disease and to track epidemiological changes over
time. However, increasing access to ART over time
makes prevalence data less reliable in understanding
transmission dynamics, which are better understood
by measuring the rates of new HIV infections.15,16
Despite the benefits of ART to enhance quality of
life, increase survival and more importantly its poten-
tial impact as a prevention tool to lower the HIV
incidence rate, the wide-scale implementation of
ART has been challenging.9
In South Africa, limited numbers of studies have
directly measured HIV incidence rates, although
these studies have consistently shown high rates
over time, yet vary by age, gender and geographic
area.3,37 HIV incidence rates have remained high,
with 45.0% amongst urban and rural women from
the general population22 and women at high risk in
Durban21 highlighting the diffuse nature of the epi-
demic. Modelling the national HIV incidence rates
amongst pregnant women attending public-sector
clinics, HIV incidence increased from 0.58% in 1990,
peaked to 6.45% in 1997 and declined to 5.41% in
2006, with the KwaZulu-Natal province experiencing
the highest rate of 8.0%.27 Using the BED-HIV-1 cap-
ture enzyme immunoassay (BED-CEIA) to measure
HIV incidence, the 2005 South African National HIV





















































































































































































































































































































































































































































































































































































































































































































































































































































































































2.4% amongst men and women aged 15–48 years.
Young women in the age group 20–29 years had the
highest rate of 5.6% compared with 0.9% amongst
men in the same age group.17 Several studies17,21,22,27
and this study confirm the persistently high
steady-state HIV incidence rates, demonstrating the
underlying transmission dynamics despite the
scaled-up prevention and treatment efforts, which
have failed to address the HIV prevention needs of
young women. This study highlights the importance
of augmenting HIV prevalence data with incidence
rate data to get a more accurate indication of trends
of HIV infection.16 Although these studies are expen-
sive and may not be feasible to undertake at the same
frequency as cross-sectional surveys, it is important in
mature HIV epidemics to supplement HIV prevalence
data with HIV incidence rate data to minimize com-
placency emanating from a stabilized prevalence and
to provide a more informative and sensitive marker of
the state of the epidemic.27
The sexual-behavioural data highlight the com-
plexity of HIV risk and prevention for women across
their life course. Although marriage is rare, many
women are sexually active and the duration of their
relationships vary substantially. In these settings
where economic options for women are limited and
their survival is dependent on having a man in their
life, child-bearing is an important facet of their iden-
tity. In this context, the traditional ‘ABC’ (abstinence,
be faithful, condom use) prevention approach is
misleading and has limited applicability.11,28 The
higher abnormal pelvic examination findings in
urban women is not surprising given that they
were recruited from the STD clinic and are likely to
be at higher risk of acquiring and reporting STIs.
The strengthening of sexual reproductive health
services, including comprehensive pregnancy preven-
tion counselling, provision of services for reducing
HIV transmission to infants and reducing maternal
mortality rates has been gaining increasing atten-
tion;29–34 and in the context of HIV programme plan-
ning,33,34 is as important for primary and secondary
HIV prevention.
Although this study has some important findings,
the benefit of longitudinal data and rigorous endpoint
ascertainment, it also has several limitations. A key
limitation is the retention rate in the study as HIV
risk behaviours of those lost to follow-up are likely
to be different from those completing the study. As
these are research-naı̈ve cohorts, the potential chal-
lenges in undertaking longitudinal studies underscore
the importance of placing more effort on retention for
future studies.35,36 HIV risk behaviours were assessed
using self-report and even though the staff received
substantial training to minimize socially desirable
responses, there is no guarantee for valid self-reported
data.37 The anal sex reporting rates, for example,
could be indicative of women’s response to infor-
mation received from study staff in the HIV
risk-reduction counselling session on the additional
increased risk of HIV acquisition through anal sex
compared with vaginal sex and could partially ac-
count for the lower reported rates of anal sex in
these study populations compared with other reported
studies from this region.21,22 Given its potential
confounding effect in testing efficacy of vaginal
products, accurate measurement of anal sex practice
is important.35
Pregnancies were determined using chemical testing
and could be an overestimate of real pregnancy
rates.38 The potential bias with selecting women
not intending to fall pregnant could impact HIV inci-
dence rates substantially; however, only 0.2% of
the pregnant volunteers were excluded at screening
and none excluded as a result of planning to
become pregnant, and this should have minimal
impact on HIV incidence in this study. It is also
clear that self-reported intention not to fall pregnant
does not correlate with actual intentions and the
importance of the selection criteria used. Although
external validity is important, the strategy used is
not generalizable even though it is important for iden-
tifying women at high risk of acquiring HIV infection.
While the pregnancy rates were high but lower than
when contraceptives are not provided by study
sites,39–41 women in the rural site recruited from
the family-planning clinic were more likely to already
be on a reliable form of contraceptive in contrast
to urban women recruited from the STD clinic. A
key lesson for future clinical trials of investigational
new drugs is the importance of counselling and
on-site provision of contraceptive services to support
fertility control and maintain the scientific integrity of
the trial through minimizing product hold. Lastly, the
urban HIV incidence rate is less stable than the rural
estimate given the smaller size of the cohort and the
shorter duration of follow-up.
Notwithstanding these study limitations and the
HIV prevalence appearing to be stabilizing,2,6,27 these
results highlight the uniquely diffuse, generalized,
hyperendemic nature of the epidemic in South Africa
and the unprecedented high HIV prevalence and inci-
dence rates across rural and urban KwaZulu-Natal.
Although these populations are not representative
of all HIV epidemics, the high prevalence and incidence
rate data underscore the importance and appropri-
ateness of including these cohorts for testing new
HIV prevention modalities. The public health imperative
for the conduct of pivotal prevention trials in this select
population in this region is particularly important to
alter HIV epidemic trajectories in this region and
globally.
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KEY MESSAGES
 The HIV incidence rates are disturbingly high among young women in rural and urban
KwaZulu-Natal, South Africa, despite reports of stabilized HIV prevalence observed in current sur-
veillance data.
 The diffuse nature of the epidemic highlights the need to enhance HIV prevention and treatment
modalities for young women.
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